estetrol   Click here for help

GtoPdb Ligand ID: 11591

Synonyms: 15 α-hydroxyestriol | 15 alpha-hydroxyestriol | Drovelis® (EMA); ; estetrol monohydrate + drospirenone | E4 | Lydisilka® (EMA); ; estetrol monohydrate + drospirenone | Nextstellis® (US); estetrol monohydrate + drospirenone
Approved drug PDB Ligand
estetrol is an approved drug (EMA & FDA (2021))
Compound class: Synthetic organic
Comment: Estetrol is a natural estrogen that is produced exclusively during pregnancy by the fetal liver. It is produced synthetically (from a plant source) for medicinal use. Estetrol has tissue selective actions [4-5], with estrogenic activity in the uterus, vagina and endometrium and estrogen antagonist activity in breast tissue.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 0
Topological polar surface area 80.92
Molecular weight 304.17
XLogP 2.82
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1[C@@H](O)[C@H]([C@@H]2O)O)C
Isomeric SMILES Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1[C@@H](O)[C@H]([C@@H]2O)O)C
InChI InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1
InChI Key AJIPIJNNOJSSQC-NYLIRDPKSA-N
No information available.
Summary of Clinical Use Click here for help
Estetrol (formulated as the monohydrate) is a component of oral contraceptives that also contain drospirenone. The FDA approved drospirenone/estetrol contraceptives in April 2021, and the EMA granted approval a few weeks later in May 2021. As a single agent estetrol has been investigated for efficacy in patients with prostatic neoplasms [2], and is in evaluation to determine its potential in managing menopausal vasomotor symptoms.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02817841 E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study Phase 3 Interventional Estetra 3
NCT02817828 E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study Phase 3 Interventional Estetra 3
NCT03361969 Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. Phase 2 Interventional Pantarhei Oncology B.V.
NCT04209543 Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) Phase 3 Interventional Estetra